| Atorvastatin-induced modulation of monocyte respiratory burst in vivo in patients with IgA nephropathy: a chronic inflammatory kidney disease. | |
| | |
MedLine Citation:
|
PMID: 20178722 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: IgA nephropathy (IgAN), the most common chronic inflammatory kidney disease, implies a considerable risk of renal failure and premature cardiovascular disease. Metabolic activation of monocytes has been suggested to be an important link between chronic inflammation, oxidative stress and the development of atherosclerosis. Oxidative stress is also involved in the progression of kidney disease. In this study we investigated the degree of monocyte activation, measured by monocyte respiratory burst in patients with IgAN, since these patients represent a fairly homogenous group of patients with chronic kidney disease, and compared the results to those in healthy subjects. As anti- inflammatory effects have been ascribed to HMG-reductase inhibitors, we also examined whether treatment with atorvastatin influenced monocyte respiratory burst. METHODS: Monocyte respiratory burst, unstimulated and stimulated by fMLP and PMA, was measured by flow cytometry in 16 patients with biopsy proven IgAN before and after 1 month of treatment with 20 mg atorvastatin/ day. Baseline values were compared to measurements in healthy subjects. Blood and urine samples, before and after statin treatment, were also analyzed for ox-LDL, inflammatory markers (CRP, MCP-1, ICAM-1, TNFR II and NGAL/MMP-9) and renal functional parameters. RESULTS: At baseline, respiratory burst of PMA-stimulated monocytes was higher in patients with IgAN as compared to that in healthy subjects (p = 0.002). After atorvastatin treatment there was a significant reduction of unstimulated, fMLP- and PMA-stimulated monocyte respiratory burst compared to baseline values (p = 0.03, p = 0.003 and p = 0.002, respectively). For ox-LDL and inflammatory serum markers we observed no significant changes. CONCLUSION: Our study demonstrates a higher monocyte respiratory burst in patients with IgAN compared to in cells from healthy controls as well as a significant reduction of this parameter after short time and low dose atorvastatin treatment. |
| | |
Authors:
|
S Lundberg; J Lundahl; I Gunnarsson; S H Jacobson |
Publication Detail:
|
Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Clinical nephrology Volume: 73 ISSN: 0301-0430 ISO Abbreviation: Clin. Nephrol. Publication Date: 2010 Mar |
Date Detail:
|
Created Date: 2010-02-24 Completed Date: 2010-06-08 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0364441 Medline TA: Clin Nephrol Country: Germany |
Other Details:
|
Languages: eng Pagination: 221-8 Citation Subset: IM |
Affiliation:
|
Nephrology Unit, Division of Medicine, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden. sigrid.lundberg@karolinska.se |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Aged Biopsy Biotransformation Creatinine / blood, urine Cytokines / blood Enzyme-Linked Immunosorbent Assay Female Flow Cytometry Follow-Up Studies Glomerular Filtration Rate Glomerulonephritis, IGA / drug therapy, metabolism*, pathology Heptanoic Acids / pharmacokinetics, therapeutic use* Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacokinetics, therapeutic use* Male Middle Aged Monocytes / drug effects, metabolism* Oxidative Stress Pyrroles / pharmacokinetics, therapeutic use* Respiratory Burst / drug effects*, physiology Treatment Outcome Young Adult |
| Chemical | |
Reg. No./Substance:
|
0/Cytokines; 0/Heptanoic Acids; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Pyrroles; 110862-48-1/atorvastatin; 60-27-5/Creatinine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Seasonal changes in blood pressure in chronic kidney disease patients.
Next Document: Do platelet function analyzer-100 testing results correlate with bleeding events after percutaneous ...